Topics:

PhI data puts Novartis on track to deliver H7N9 vaccine

Tools

Novartis ($NVS) has posted positive Phase I data for its H7N9 vaccine, which is now in large-scale production. The trial found two doses of the adjuvanted cell culture vaccine immunologically protected 85% of participants. Release

Filed Under

Comments